Fit-for-purpose: Liver Biopsies in MASH clinical trials and patient management post-drug approval

The recent FDA approval of Rezdiffra (resmetirom) for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH) has marked a significant milestone in the management of this complex liver disease. In light of this development, a panel of distinguished experts convened for a webcast titled "'Fit for Purpose': The Evolving Role of Liver Biopsies in MASH Clinical Trials and Patient Management Post-drug Approval." The webcast, moderated by Professor Nikolai Naoumov, brought together Dr. Arun Sanyal, Dr. David Kleiner, and Dr. Timothy Kendall to discuss the implications of Rezdiffra's approval on clinical practice and future drug development in MASH.
Topics covered:
- The role of liver biopsy in MASH diagnosis and assessing treatment response in clinical practice
- The use of non-invasive tests (NITs) in MASH patient diagnosis and monitoring
- The role of liver biopsy in analyzing the efficacy of combination trials and addressing the heterogeneity in MASH
- The importance of pairing liver biopsies with molecular pathology to guide personalized treatment strategies
- The potential of digital pathology and artificial intelligence in MASH assessment
What are your thoughts on the role of liver biopsies in the management of MASH? If you have any questions for our expert panel, let us know in the comments below!